Current treatments
Comparison of cyclophosphamide-thalidomide-dexamethasone to bortezomib-cyclophosphamide-dexamethasone as induction therapy for multiple myeloma patients in Brazil. Vigolo S et al. Hematol Oncol Stem Cell Ther. 2017 Jun 15. pii: S1658-3876(17)30082-1. doi: 10.1016/j.hemonc.2017.05.027. [Epub ahead of print]. Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone. Vogl DT et al. Leuk Lymphoma. 2017 Jun 22:1-8. doi: 10.1080/10428194.2017.1334125. [Epub ahead of…
Details